BeyondSpring Pharmaceuticals is a global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes. The Company is developing treatments in two of the world’s largest markets, China and the United States. BeyondSpring’s first-in-class lead asset plinabulin, a selective immunomodulating microtubule-binding agent, is being developed as a “pipeline in a drug” with potential to be an anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). In the DUBLIN-3 Phase 3 study, the plinabulin and docetaxel combination met the primary endpoint of extending overall survival, compared to docetaxel alone in 2nd/3rd line non-small cell lung cancer (EGFR wild type). In addition, the plinabulin and G-CSF combination for the prevention of CIN has demonstrated positive Phase 3 data, for which it received Breakthrough status in the U.S. and China. Plinabulin is also currently being studied as part of other immuno-oncology (IO) combination regimens that include radiation and/or checkpoint inhibitors for the treatment of a number of cancers. Lastly, BeyondSpring also has three preclinical IO assets and majority ownership in its subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation drug discovery platform.
Free account • No credit card • 5 profiles/day
The widely used BeyondSpring email format is {first_initial}{last}@beyondspringpharma.com (e.g. jsmith@beyondspringpharma.com), which is used 75% of the time.
| BeyondSpring Email Formats | Example Email Formats | Adoption |
|---|---|---|
| {first_initial}{last} | jsmith@beyondspringpharma.com |
75%
|
| Other formats | — |
25%
|
Adoption = share of company emails using each format — not a verification or accuracy score.
Gilead Sciences
Biotechnology Research • 10,001+ employees • Bratislava, Slovakia
Novartis
Pharmaceutical Manufacturing • 10,001+ employees • Sofia, Bulgaria
Rexahn Pharmaceuticals
Pharmaceutical Manufacturing • 2-10 employees • Rockville, United States
Allorion Therapeutics
Pharmaceutical Manufacturing • 11-50 employees • Guangzhou, China
CNBX Pharmaceuticals
Pharmaceutical Manufacturing • 2-10 employees • Bethesda, United States
Forbius (Formation Biologics)
Pharmaceutical Manufacturing • 11-50 employees • Austin, United States
What is BeyondSpring email format?
The widely used BeyondSpring email format is {first_initial}{last} (e.g. jsmith@beyondspringpharma.com) with 75% adoption across the company.
What is BeyondSpring customer service number?
To contact BeyondSpring customer service number in your country click here to find.
Who is the CEO of BeyondSpring?
Lan Huang is the CEO of BeyondSpring. To contact Lan Huang email at lan_123_2000@yahoo.com or lan.huang@beyondspringpharma.com. Or you may call +1.6465284184
Who are the decision makers in BeyondSpring?
The decision makers in BeyondSpring are Cornelia Chen, Joy Jia, June L, etc. Click to Find BeyondSpring decision makers emails.
What types of cancer therapies does BeyondSpring Pharmaceuticals develop?
BeyondSpring Pharmaceuticals specializes in developing innovative therapies for oncology and immuno-oncology. The company focuses on creating treatments that target various types of cancer, aiming to improve clinical outcomes for patients. Their pipeline includes novel drug candidates that are designed to enhance the effectiveness of existing therapies and provide new options for patients with unmet medical needs.
How does BeyondSpring Pharmaceuticals approach clinical trials?
BeyondSpring Pharmaceuticals employs a rigorous and comprehensive approach to clinical trials, ensuring that their therapies are thoroughly tested for safety and efficacy. The company conducts trials in compliance with international regulatory standards, and they actively engage with healthcare professionals and patients to gather valuable insights. Their commitment to transparency and ethical practices ensures that the clinical trial process is conducted with the highest level of integrity.
In which markets does BeyondSpring Pharmaceuticals operate?
BeyondSpring Pharmaceuticals operates primarily in two of the world’s largest markets: China and the United States. The company is strategically positioned to leverage the growing demand for innovative cancer therapies in these regions. By focusing on both markets, BeyondSpring aims to address the diverse needs of patients and healthcare providers, facilitating access to cutting-edge treatments.
What is the significance of immuno-oncology in BeyondSpring's research?
Immuno-oncology is a critical area of research for BeyondSpring Pharmaceuticals as it represents a transformative approach to cancer treatment. This field focuses on harnessing the body’s immune system to fight cancer more effectively. BeyondSpring is dedicated to developing therapies that not only target cancer cells directly but also enhance the immune response, potentially leading to better patient outcomes and fewer side effects compared to traditional therapies.
How can healthcare professionals collaborate with BeyondSpring Pharmaceuticals?
Healthcare professionals interested in collaborating with BeyondSpring Pharmaceuticals can reach out through the company's official website. BeyondSpring values partnerships with clinicians, researchers, and institutions to advance cancer research and improve treatment protocols. The company is open to discussions regarding clinical trials, research collaborations, and other opportunities that align with their mission to innovate in oncology.
What resources does BeyondSpring provide for patients and caregivers?
BeyondSpring Pharmaceuticals is committed to supporting patients and caregivers through various resources. The company provides educational materials about their therapies, information on ongoing clinical trials, and access to support networks. They aim to empower patients and caregivers with knowledge about cancer treatment options and to facilitate connections with healthcare professionals who can provide guidance throughout the treatment journey.
